NLS Pharmaceutics Warrant
NLSPW
NLSPW was delisted on the 30th of October, 2025.
3 hedge funds and large institutions have $1.71K invested in NLS Pharmaceutics Warrant in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.
50% more capital invested
Capital invested by funds: $1.14K → $1.71K (+$572)
2.52% more ownership
Funds ownership: 0.22% → 2.74% (+2.5%)
0% more funds holding
Funds holding: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$214 |
| 2 |
CS
Clear Street
New York
|
+$2 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$237 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CS
1
Clear Street
New York
| $1.16K | +$2 | +120 | +0.2% |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $309 | +$214 | +16,333 | New |
|
|
AC
3
Armistice Capital
New York
| $250 | – | – | – |
|
|
4
Citadel Advisors
Miami,
Florida
| – | -$237 | -18,381 | Closed |
|
NLSPW Hedge Fund Activity: Q2 2025 in Review
3 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in NLS Pharmaceutics Warrant (NLSPW) for Q2 2025, worth a combined $1.71K — up 50% from $1.14K a quarter earlier.
Fund positioning in NLSPW was balanced in Q2 2025: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $214. The largest seller was Citadel Advisors, exiting entirely with an estimated $237 sold.
- 3 institutional investors held NLS Pharmaceutics Warrant (NLSPW) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $1.71K of NLS Pharmaceutics Warrant stock for Q2 2025, up 50% quarter-over-quarter.
- 1 fund opened new NLS Pharmaceutics Warrant positions in Q2 2025 and 1 closed out, a net change of 0 holders.
- The largest NLS Pharmaceutics Warrant buyer in Q2 2025 was Susquehanna International Group, an estimated $214 added.
- The largest NLS Pharmaceutics Warrant seller in Q2 2025 was Citadel Advisors, an estimated $237 sold.
Based on aggregated 13F filings for Q2 2025.